Products & Services

CNS-3D Brain Organoids

Assay-ready human cortical organoids for functional studies of CNS safety and drug efficacy. Identify drug-induced changes in neuronal network activity to support more predictive CNS therapeutic development.

Measure Functional Neural Activity in Human Cortical Organoids

CNS-3D Brain Organoids are human cortical organoids designed for predictive drug assessment. Derived from iPSC-based neural progenitor cells, they self-organize into balanced neuron–astrocyte co-cultures that form functional neural networks with spontaneous activity.

This activity is measured using calcium imaging to assess drug-induced changes in neuronal function and can be multiplexed with complementary endpoints spanning viability, imaging, and molecular analysis. CNS-3D Brain Organoids are available as assay-ready products for in-house workflows or through CNS Services for end-to-end study design, execution, and analysis.

Key Advantages

Functional
Neural Activity

Measure drug-induced changes in neuronal network activity.

Flexible
Study Scale

Flexibly run studies in 24-, 48-, 96-, or 384-replicate formats.

Reproducible Performance

Standardized production and QC support consistent performance across studies.

Application

CNS Toxicity

Predict CNS toxicity risk by measuring drug-induced changes in neuronal network activity.

By measuring functional disruption of neuronal network activity, CNS-3D enables confident identification of neurotoxic liabilities across diverse modalities, outperforming animal models by 13x. CNS-3D Brain Organoids achieve 83% sensitivity and 89% specificity in predicting clinical seizure liability for small molecules, and 92% sensitivity and 92% specificity for ASOs.

Learn More

Sensitivity and specificity comparison for small molecule seizure risk prediction, demonstrating superior performance of CNS-3D versus alternative models.

Application

Gene Therapy

Prioritize gene therapy vectors using functional, human data.

CNS-3D Brain Organoids integrate assessment of transduction efficiency, toxicity, and functional impact in a single model. In AAV studies, this approach resolves serotype- and promoter-dependent differences in vector performance and detects disruption of neuronal network activity before overt viability loss.

Learn More

Representative images of AAV transduction in CNS-3D Brain Organoids, demonstrating clear serotype- and promoter-dependent GFP expression.

Offerings

Products & Services

Access CNS-3D Brain Organoids with assay-ready products for in-house studies or through CNS Services for end-to-end study design, execution, and analysis.